Drugs / V3G CH848 mRNA-Tr2
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05903339 Background | Aug 2023 → Dec 2026 expected | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V3G CH848 mRNA-Tr2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05903339 ↗ |
| Modality | Messenger RNA (mRNA) | “This immunogen will be boosted with an mRNA LNP (V3G CH848 mRNA-Tr2), encoding a soluble Env trimer which does not utilize the ferritin NP design.” NCT05903339 ↗ |